Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

PURPOSE: CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses follo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Sharma, Padmanee, Siefker-Radtke, Arlene, de Braud, Filippo, Basso, Umberto, Calvo, Emiliano, Bono, Petri, Morse, Michael A., Ascierto, Paolo A., Lopez-Martin, Jose, Brossart, Peter, Rohrberg, Kristoffer, Mellado, Begoña, Fischer, Bruce S., Meadows-Shropshire, Stephanie, Abdel Saci, Callahan, Margaret K., Rosenberg, Jonathan
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
RAPID COMMUNICATION
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6879315/
https://ncbi.nlm.nih.gov/pubmed/31100038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00538
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky